Nov 14th 2012 - Edison Investment Research today published a report on Synergy Health (SYR.L, LSE:SYR, LON:SYR) entitled "US & Asia Drive Growth". In summary, the report says:
Synergy Health produced a strong H112 performance, despite economic woes in the UK and European markets. The strategy of rolling out from the UK into other markets is reaping benefits. Near-term earnings will be underpinned by the SRI acquisition and margin improvement as the turnaround continues. Medium-term growth should be driven by further US and Asian expansion. An 11.2% five-year CAGR EPS growth and 14.7x P/E suggests the shares are currently fairly valued.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »